biostudies-literatureUnknown13Lin SY<b>Background:</b> Whether diabetes mellitus (DM) patients with chronic kidney disease (CKD) can glean individual renal benefit from dihydropyridine calcium channel blockers (DCCBs) remains to be determined. We conducted a nationwide, population-based, propensity score matching cohort study to examine the effect of DCCBs on CKD progression in DM patients with CKD. <b>Methods:</b> One million individuals were randomly sampled from Taiwan's National Health Insurance Research Database. The study cohort consisted of DM patients with CKD who used DCCBs. The comparison cohort was propensity-matched for demographic characteristics and comorbidities. The endpoint was advanced CKD or end-stage renal disease (ESRD). The Cox proportional hazards model was used to calculate the risks. <b>Results:</b> Frontiers in pharmacology786203https://www.ebi.ac.uk/biostudies/studies/S-EPMC8959929biostudies-literatureChronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study.PMC8959929Hsu WHLin CLLin CCKao CHHsu CYLin SYfalseChronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study.<b>Background:</b> Whether diabetes mellitus (DM) patients with chronic kidney disease (CKD) can glean individual renal benefit from dihydropyridine calcium channel blockers (DCCBs) remains to be determined. We conducted a nationwide, population-based, propensity score matching cohort study to examine the effect of DCCBs on CKD progression in DM patients with CKD. <b>Methods:</b> One million individuals were randomly sampled from Taiwan's National Health Insurance Research Database. The study cohort consisted of DM patients with CKD who used DCCBs. The comparison cohort was propensity-matched for demographic characteristics and comorbidities. The endpoint was advanced CKD or end-stage renal disease (ESRD). The Cox proportional hazards model was used to calculate the risks. <b>Results:</b> 2022-01-01T00:00:00Z20222025-04-04T07:35:04.144Z2025-04-04T07:35:04.144ZS-EPMC89599293535572810.3389/fphar.2022.786203